<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155215</url>
  </required_header>
  <id_info>
    <org_study_id>SD46</org_study_id>
    <nct_id>NCT05155215</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19&#xD;
      CAR-T cells in adult R/R Mantle Cell Lymphoma subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0</measure>
    <time_frame>Up to 28 days after IM19 CAR-T cell infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At 3 months after IM19 CAR-T cell infusion</time_frame>
    <description>ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to Lugano(2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At 28 days and 6 months after IM19 CAR-T cell infusion</time_frame>
    <description>ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to Lugano(2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 weeks after IM19 CAR-T cell infusion</time_frame>
    <description>PFS, defined as the time from CAR-T cell infusion to the first occurrence of disease progression or death from any cause (whichever occurs first) , as determined by the investigator according to Lugano(2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 24 weeks after IM19 CAR-T cell infusion</time_frame>
    <description>DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to Lugano(2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 weeks after CAR-T cell infusion</time_frame>
    <description>OS , defined as the time from IM19 CAR-T cell infusion to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)</measure>
    <time_frame>Up to 24 weeks after IM19 CAR-T cell infusion</time_frame>
    <description>The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-therapeutic IM19 CAR-T cells antibody</measure>
    <time_frame>Up to 24 weeks after IM19 CAR-T cell infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>IM19 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T cells</intervention_name>
    <description>IM19 CAR-T cells will be administered at dose level: 100×10^6 CAR-T cells or 200×10^6 CAR-T cells</description>
    <arm_group_label>IM19 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m^2 per day for 3 days (IV)</description>
    <arm_group_label>IM19 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 per day for 3 days (IV)</description>
    <arm_group_label>IM19 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with relapsed or refractory mantle cell lymphoma, diagnosed as CD19 positive&#xD;
             by cytology or histology；&#xD;
&#xD;
          -  Subjects have measurable positive lesion according to Lugano Classification;&#xD;
&#xD;
          -  ≥ 18 years old;&#xD;
&#xD;
          -  Expected survival is greater than 3 months；&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
          -  The toxicity caused by the previous treatment has stabilized or recovered to ≤1 level&#xD;
             (except for the case where the investigator judges that it has no clinical&#xD;
             significance);&#xD;
&#xD;
          -  Women of childbearing age who had a negative blood pregnancy test before the start of&#xD;
             the trial and agreed to take effective contraceptive measures during the trial period&#xD;
             until the last follow-up; male subjects with fertility partners agreed to take&#xD;
             effective contraceptive measures during the trial period until the last follow-up;&#xD;
&#xD;
          -  Adequate organ function;&#xD;
&#xD;
          -  Adequate vascular access for leukapheresis procedure;&#xD;
&#xD;
          -  Volunteer to participate in this trial and sign on the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) involvement by lymphoma;&#xD;
&#xD;
          -  Received allo-hematopoietic stem cell transplantation or organ transplantation therapy&#xD;
             previously；&#xD;
&#xD;
          -  Subjects with cardiac atrial or cardiac ventricular lymphoma involvement；&#xD;
&#xD;
          -  Serous effusion with symptoms of compression;&#xD;
&#xD;
          -  History of autoimmune disease (eg Crohn's disease, rheumatoid arthritis, systemic&#xD;
             lupus) within the last 2 years;&#xD;
&#xD;
          -  Presence of acute or chronic graft-versus-host disease (GVHD);&#xD;
&#xD;
          -  Use prohibited drugs or treatments within a specified period of time before cell&#xD;
             collection；&#xD;
&#xD;
          -  Received anti-CD19 target therapy (unless the CD19 target test is still positive);&#xD;
&#xD;
          -  Received CAR-T cell therapy;&#xD;
&#xD;
          -  Received the study drug within 4 weeks before cell collection. However, if the trial&#xD;
             treatment is invalid or the disease progresses, and at least 5 half-lives have passed&#xD;
             before the cell collection, it is allowed to enter the group;&#xD;
&#xD;
          -  Received radiotherapy within 6 weeks prior to cell collection, including large bone&#xD;
             marrow areas such as the sternum or pelvis. Subjects who have progressed in the&#xD;
             radiotherapy site or have PET-positive lesions in other non-irradiated sites are&#xD;
             eligible to be included in the group;&#xD;
&#xD;
          -  Received donor lymphocyte infusion (DLI) within 6 weeks before CAR-T cell infusion;&#xD;
&#xD;
          -  If anti-PD1, PD-L1 and other immunotherapies have been used before CAR-T cell&#xD;
             reinfusion, at least 5 half-lives must elapse between the last medication and before&#xD;
             CAR-T cell reinfusion;&#xD;
&#xD;
          -  History or presence of CNS disorder, such as seizure disorder, cerebrovascular&#xD;
             ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posteriorreversible&#xD;
             encephalopathy syndrome, or any autoimmune disease with CNS involvement;&#xD;
&#xD;
          -  Received autologous transplantation within 6 weeks before the start of screening;&#xD;
&#xD;
          -  Subjects has HBV, HCV, HIV ,EBV,ECV or syphilis infection at the time of screening;&#xD;
&#xD;
          -  Live vaccine received within 6 weeks before the start of screening;&#xD;
&#xD;
          -  History of myocardial infarction, cardiac angioplasty or stenting, unstable&#xD;
             angina,active arrhythmias, or other clinically significant cardiac disease within 6&#xD;
             months of enrollment;&#xD;
&#xD;
          -  History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of&#xD;
             enrollment;&#xD;
&#xD;
          -  History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (eg,&#xD;
             cervix, bladder, breast) unless disease-free for at least 3 years；&#xD;
&#xD;
          -  Presence of fungal, bacterial, viral, or other infection that is uncontrolled or&#xD;
             requiring intravenous (IV) antimicrobials for management. Simple urinary tract&#xD;
             infection (UTI) and bacterial pharyngitis are permitted if the investigator evaluates&#xD;
             that it can be controlled by treatment, they can be included in the group;&#xD;
&#xD;
          -  In the investigator's judgment, the subject is unlikely to complete all&#xD;
             protocol-required study visits or procedures, including follow-up visits, or comply&#xD;
             with the study requirements for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmei Jing, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Wu, MD</last_name>
    <phone>+8615801390058</phone>
    <email>wufei@immunochina.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

